Cancer treatments are becoming more personal. The Food and Drug Administration recently gave accelerated approval for Keytruda, a pre-existing drug from Merck, for use on patients diagnosed with solid tumors containing a specific biomarker. Rather than basing treatment on where the mutation originated, Keytruda will be used to treat microsatellite instability-high (MSI-H) cancers, those that are mismatch repair deficient (dMMR) and are otherwise not able to be surgically removed. These types of tumors affect how the DNA is repaired inside the cell.
Via: Regulatory Affairs Professionals Society
via Engadget RSS Feedhttp://ift.tt/2qWEG1v